title: Evidence that a transient enhancement of endogenous hematopoiesis contributes significantly to the favorable outcome following interleukin 1 pretreatment and allogeneic bone marrow transplantation.
abstract: The administration of IL-1, a potent radioprotective cytokine, before allogeneic BMT is associated with an early transient increase of circulating granulocytes, successful engraftment, and accelerated multilineage hematopoietic recovery. We have examined the effects of IL-1 alpha pretreatment on the engraftment of an allogeneic BMT unable to sustain survival by itself after a lethal irradiation: (1) transplantation of a limited amount of marrow cells and (2) transplantation several days after irradiation. IL-1 was unable to allow the engraftment of an early quantitatively inadequate BMT. However, delayed BMT with limited amounts of marrow cells was associated with engraftment in IL-1 pretreated recipients. Engraftment of a late (day 12) BMT in these IL-1-pretreated mice was comparable to the engraftment of a similar day 12 allogeneic BMT in non-IL-1-pretreated mice rescued from the lethal irradiation by an early (day 1) syngeneic graft. These findings demonstrate that IL-1 pretreatment can result in a dissociation between BMT-induced survival and engraftment and suggest that the favorable effects of IL-1 pretreatment in an allogeneic BMT setting are mainly mediated through a transient enhancement of endogenous hematopoiesis and not through a direct effect on the allogeneic stem cells present in the marrow graft.
authors.affiliation: Histocompatibility and Immuno-Molecular Therapeutics Laboratory, E.T.S. Franche-Comte, France.
authors.forename: V
authors.initials: V
authors.lastname: Herve
authors.forename: M
authors.initials: M
authors.lastname: Mabed
authors.forename: V
authors.initials: V
authors.lastname: Laithier
authors.forename: J J
authors.initials: JJ
authors.lastname: Pavy
authors.forename: R
authors.initials: R
authors.lastname: Angonin
authors.forename: E
authors.initials: E
authors.lastname: Contassot
authors.forename: J M
authors.initials: JM
authors.lastname: Certoux
authors.forename: J Y
authors.initials: JY
authors.lastname: Cahn
authors.forename: P
authors.initials: P
authors.lastname: Herve
authors.forename: P
authors.initials: P
authors.lastname: Tiberghien
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects*; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D011837:Radiation-Protective Agents / Q000494:pharmacology*; D014916:Whole-Body Irradiation
chemical_list: D007375:Interleukin-1; D011837:Radiation-Protective Agents